Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 19 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
CORUM PHARMA from Wielsbeke, company number BE0763652492, closed financial year 2026 with a result of € 67,004 after tax. For that financial year CORUM PHARMA recorded a gross margin of € 104,535 and equity of € 1.7 million. Compared with financial year 2025, the result moved from € 72,475 to € 67,004. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 26, 2026.
€ 1.7 million
▲ 4% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 67,004
▼ 8% vs 2025
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 1.7 million.
People and assets in 2026
€ 2,024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 26,542
▼ 32% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 496,365
▼ 11% vs 2025
€ 93,468 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 1,958
▼ 13% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 12,870
▼ 56% vs 2025
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 107,825 | € 118,643 | € 111,987 | € 104,535 | ▼ 7% |
| Profit after taxes | € 82,501 | € 79,937 | € 72,475 | € 67,004 | ▼ 8% |
| Equity | € 1,518,317 | € 1,598,254 | € 1,670,729 | € 1,737,734 | ▲ 4% |
| Total debts | € 785,590 | € 770,214 | € 664,443 | € 589,763 | ▼ 11% |
| Retained profit | € 1,468,317 | € 1,548,254 | € 1,620,729 | € 1,687,734 | ▲ 4% |
| Bank debt | € 676,392 | € 657,606 | € 558,221 | € 496,365 | ▼ 11% |
| Balance sheet total | € 2,303,907 | € 2,368,468 | € 2,335,172 | € 2,327,496 |
Key figures of CORUM PHARMA, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to CORUM PHARMA?
What happened at CORUM PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 67,004 (▼ 8% vs 2025). Source: NBB ↗
- New establishment in Wielsbeke. KBO
- Start of the company according to the CBE. KBO
In short
From € 82,501 profit in 2023 to € 67,004 profit in 2026.
Paid € 79,154 in corporate taxes since 2023.
Best year ever: 2023, with € 82,501 profit.
Establishments
Establishment units
Physical locations of this company
Heirweg 144 A
8710 Wielsbeke
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0763.652.492
- VAT number
- BE 0763.652.492
- Registered office
- Heirweg 144 A, 8710 Wielsbeke
- Names & denominations
- CORUM PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 February 2021
- Peppol
- Active · Active since 4 Jun 2025
- Activities · NACE
Activiteiten van holdings
Holdings